Renal Toxicities of Targeted Therapies

Targeted Oncology

Volumn 10, Issue 4, 2015, Pages 487-499

  Abbas, Anum ^a   Mirza, Mohsin M ^a   Ganti, Apar Kishor ^b   Tendulkar, Ketki ^c  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; AXITINIB; BEVACIZUMAB; CALCITRIOL; CERITINIB; CETUXIMAB; CRIZOTINIB; DABRAFENIB; DASATINIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; EXEMESTANE; IMATINIB; IPILIMUMAB; NILOTINIB; PANITUMUMAB; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRANSIENT RECEPTOR POTENTIAL CHANNEL M6; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VEMURAFENIB; ANTINEOPLASTIC AGENT; VASCULOTROPIN A;

ACUTE KIDNEY FAILURE; ADVANCED CANCER; ANTIANGIOGENIC THERAPY; BLOOD PRESSURE MONITORING; BREAST CANCER; CHRONIC KIDNEY FAILURE; CHRONIC MYELOID LEUKEMIA; CREATININE BLOOD LEVEL; DIET THERAPY; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG TOLERABILITY; EOSINOPHILIA; FEVER; FOCAL GLOMERULOSCLEROSIS; GASTROENTERITIS; GASTROINTESTINAL STROMAL TUMOR; GLOMERULUS FILTRATION RATE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INCIDENCE; INTERSTITIAL NEPHRITIS; KIDNEY CARCINOMA; KIDNEY CYST; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TUBULE ACIDOSIS; LIFESTYLE MODIFICATION; LUNG EMBOLISM; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NEPHROTIC SYNDROME; NEPHROTOXICITY; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN BINDING; PROTEINURIA; RASH; REVIEW; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; SUBSTITUTION THERAPY; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; KIDNEY DISEASE; KIDNEY NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; KIDNEY DISEASES; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84949103875     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-015-0368-7     Document Type: Review

References (93)

1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–6. doi:10.1056/NEJM197111182852108
2. Gurevich F, Perazella MA (2009) Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 122(4):322–8. doi:10.1016/j.amjmed.2008.11.025
3. Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R et al (2007) VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 104(47):18363–70. doi:10.1073/pnas.0708865104
4. Usui J, Glezerman IG, Salvatore SP, Chandran CB, Flombaum CD, Seshan SV (2014) Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Hum Pathol 45(9):1918–27. doi:10.1016/j.humpath.2014.05.015
5. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J et al (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358(11):1129–36. doi:10.1056/NEJMoa0707330
6. Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis Off J Natl Kidney Found 49(2):186–93. doi:10.1053/j.ajkd.2006.11.039
7. Zhu X, Stergiopoulos K, Wu S (2009) Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 48(1):9–17. doi:10.1080/02841860802314720
8. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9(2):117–23. doi:10.1016/S1470-2045(08)70003-2
9. Li Y, Li S, Zhu Y, Liang X, Meng H, Chen J et al (2014) Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis. J Clin Hypertens 16(3):177–85. doi:10.1111/jch.12273
10. Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA et al (2013) Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 18(3):273–80. doi:10.1634/theoncologist.2012-0339
11. Qi WX, He AN, Shen Z, Yao Y (2013) Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol 76(3):348–57. doi:10.1111/bcp.12149
12. Qi WX, Lin F, Sun YJ, Tang LN, He AN, Yao Y et al (2013) Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother Pharmacol 71(2):431–9. doi:10.1007/s00280-012-2025-5
13. Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M et al (2015) Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 121(2):311–9. doi:10.1002/cncr.28972
14. Hood JD, Meininger CJ, Ziche M, Granger HJ (1998) VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 274(3 Pt 2):H1054–8
15. Zou AP, Cowley AW Jr (1999) Role of nitric oxide in the control of renal function and salt sensitivity. Curr Hypertens Rep 1(2):178–86
16. Feihl F, Liaudet L, Waeber B, Levy BI (2006) Hypertension: a disease of the microcirculation? Hypertension 48(6):1012–7. doi:10.1161/01.HYP.0000249510.20326.72
17. Harper RN, Moore MA, Marr MC, Watts LE, Hutchins PM (1978) Arteriolar rarefaction in the conjunctiva of human essential hypertensives. Microvasc Res 16(3):369–72
18. Gonzalez-Pacheco FR, Deudero JJ, Castellanos MC, Castilla MA, Alvarez-Arroyo MV, Yague S et al (2006) Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2. Am J Physiol Heart Circ Physiol 291(3):H1395–401. doi:10.1152/ajpheart.01277.2005
19. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ et al (2010) Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102(9):596–604. doi:10.1093/jnci/djq091
20. Isobe T, Uchino K, Makiyama C, Ariyama H, Arita S, Tamura S et al (2014) Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan. Anticancer Res 34(4):2035–40
21. Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A et al (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol Off J Eur Soc Med Oncol / ESMO 20(5):807–15. doi:10.1093/annonc/mdn713
22. Pande A, Lombardo J, Spangenthal E, Javle M (2007) Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res 27(5B):3465–70
23. Lemmens L, Claes V, Uzzell M (2008) Managing patients with metastatic colorectal cancer on bevacizumab. Br J Nurs 17(15):944–9
24. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC (2010) VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 46(2):439–48. doi:10.1016/j.ejca.2009.11.001
25. Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G (2007) Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis Off J Natl Kidney Found 50(2):203–18. doi:10.1053/j.ajkd.2007.04.025
26. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427–34. doi:10.1056/NEJMoa021491
27. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N et al (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111(5):707–16. doi:10.1172/JCI17423
28. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR et al (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290(2):H560–76. doi:10.1152/ajpheart.00133.2005
29. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A et al (2003) Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278(15):12605–8. doi:10.1074/jbc.C300012200
30. Grenon NN (2013) Managing toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancer. Clin J Oncol Nurs 17(4):425–33. doi:10.1188/13.CJON.425-433
31. Izzedine H, Soria JC, Escudier B (2013) Proteinuria and VEGF-targeted therapies: an underestimated toxicity? J Nephrol 26(5):807–10. doi:10.5301/jn.5000307
32. Vigneau C, Lorcy N, Dolley-Hitze T, Jouan F, Arlot-Bonnemains Y, Laguerre B et al (2014) All anti-vascular endothelial growth factor drugs can induce ‘pre-eclampsia-like syndrome’: a RARe study. Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Renal Assoc 29(2):325–32. doi:10.1093/ndt/gft465
33. Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA (2007) Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 7(10):2350–60. doi:10.1111/j.1600-6143.2007.01928.x
34. Blanco S, Bonet J, Lopez D, Casas I, Romero R (2005) ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis. Kidney Int Suppl 93:S10–4. doi:10.1111/j.1523-1755.2005.09303.x
35. Agabiti-Rosei E (2003) Structural and functional changes of the microcirculation in hypertension: influence of pharmacological therapy. Drugs 63(Spec No):19–29
36. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S (2012) Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf 11(Suppl 1):S9–19. doi:10.1517/14740338.2011.606213
37. Maliakal P, Ledford A (2010) Electrolyte and protein imbalance following anti-EGFR therapy in cancer patients: a comparative study. Exp Ther Med 1(2):307–11. doi:10.3892/etm_00000047
38. Quamme GA (1997) Renal magnesium handling: new insights in understanding old problems. Kidney Int 52(5):1180–95
39. Voets T, Nilius B, Hoefs S, van der Kemp AW, Droogmans G, Bindels RJ et al (2004) TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem 279(1):19–25. doi:10.1074/jbc.M311201200
40. Groenestege WM, Thebault S, van der Wijst J, van den Berg D, Janssen R, Tejpar S et al (2007) Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 117(8):2260–7. doi:10.1172/JCI31680
41. Tejpar S, Piessevaux H, Claes K, Piront P, Hoenderop JG, Verslype C et al (2007) Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 8(5):387–94. doi:10.1016/S1470-2045(07)70108-0
42. Fakih M (2008) Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia. Oncology (Williston Park) 22(1):74–6
43. Murdoch DL, Forrest G, Davies DL, McInnes GT (1993) A comparison of the potassium and magnesium-sparing properties of amiloride and spironolactone in diuretic-treated normal subjects. Br J Clin Pharmacol 35(4):373–8
44. Blanchard A, Vargas-Poussou R, Vallet M, Caumont-Prim A, Allard J, Desport E et al (2015) Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome. J Am Soc Nephrol JASN 26(2):468–75. doi:10.1681/ASN.2014030293
45. Cao Y, Liu L, Liao C, Tan A, Gao F (2010) Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer. Cancer Chemother Pharmacol 66(1):37–42. doi:10.1007/s00280-009-1131-5
46. Giusti RM, Cohen MH, Keegan P, Pazdur R (2009) FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer. Oncologist 14(3):284–90. doi:10.1634/theoncologist.2008-0254
47. Whang R, Welt LG (1963) Observations in experimental magnesium depletion. J Clin Invest 42:305–13. doi:10.1172/JCI104717
48. Fakih MG, Wilding G, Lombardo J (2006) Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer 6(2):152–6. doi:10.3816/CCC.2006.n.033
49. Marcolino MS, Boersma E, Clementino NC, Macedo AV, Marx-Neto AD, Silva MH et al (2011) Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol Off J Eur Soc Med Oncol / ESMO 22(9):2073–9. doi:10.1093/annonc/mdq715
50. Gafter-Gvili A, Ram R, Gafter U, Shpilberg O, Raanani P (2010) Renal failure associated with tyrosine kinase inhibitors—case report and review of the literature. Leuk Res 34(1):123–7. doi:10.1016/j.leukres.2009.07.009
51. Pou M, Saval N, Vera M, Saurina A, Sole M, Cervantes F et al (2003) Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 44(7):1239–41. doi:10.1080/1042819031000079140
52. Foringer JR, Verani RR, Tjia VM, Finkel KW, Samuels JA, Guntupalli JS (2005) Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Ann Pharmacother 39(12):2136–8. doi:10.1345/aph.1G131
53. Francois H, Coppo P, Hayman JP, Fouqueray B, Mougenot B, Ronco P (2008) Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. Am J Kidney Dis Off J Natl Kidney Found 51(2):298–301. doi:10.1053/j.ajkd.2007.10.039
54. Takikita-Suzuki M, Haneda M, Sasahara M, Owada MK, Nakagawa T, Isono M et al (2003) Activation of Src kinase in platelet-derived growth factor-B-dependent tubular regeneration after acute ischemic renal injury. Am J Pathol 163(1):277–86. doi:10.1016/S0002-9440(10)63651-6
55. Vuky J, Isacson C, Fotoohi M, dela Cruz J, Otero H, Picozzi V et al (2006) Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma. Investig New Drugs 24(1):85–8. doi:10.1007/s10637-005-4543-z
56. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K et al (2006) Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354(19):2006–13. doi:10.1056/NEJMoa051140
57. O’Sullivan S, Horne A, Wattie D, Porteous F, Callon K, Gamble G et al (2009) Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 94(4):1131–6. doi:10.1210/jc.2008-2324
58. Aleman JO, Farooki A, Girotra M (2014) Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies. Endocr Relat Cancer 21(3):R247–59. doi:10.1530/ERC-12-0400
59. Steinberg M (2007) Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 29(11):2289–308. doi:10.1016/j.clinthera.2007.11.005
60. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682):399–401. doi:10.1126/science.1099480
61. Holstein SA, Stokes JB, Hohl RJ (2009) Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leuk Res 33(2):344–7. doi:10.1016/j.leukres.2008.07.029
62. Ozkurt S, Temiz G, Acikalin MF, Soydan M (2010) Acute renal failure under dasatinib therapy. Ren Fail 32(1):147–9. doi:10.3109/08860220903391226
63. Kaiafa G, Kakaletsis N, Savopoulos C, Perifanis V, Giannouli A, Papadopoulos N et al (2014) Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report. J Clin Pharm Ther 39(1):102–5. doi:10.1111/jcpt.12107
64. Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG et al (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res 15(19):6232–40. doi:10.1158/1078-0432.CCR-09-0224
65. Wallace E, Lyndon W, Chumley P, Jaimes EA, Fatima H (2013) Dasatinib-induced nephrotic-range proteinuria. Am J Kidney Dis Off J Natl Kidney Found 61(6):1026–31. doi:10.1053/j.ajkd.2013.01.022
66. Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13:513–609. doi:10.1146/annurev.cellbio.13.1.513
67. Liang W, Kujawski M, Wu J, Lu J, Herrmann A, Loera S et al (2010) Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. Clin Cancer Res Off J Am Assoc Cancer Res 16(3):924–35. doi:10.1158/1078-0432.CCR-09-1486
68. Kaplan B, Qazi Y, Wellen JR (2014) Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev 28(3):126–33. doi:10.1016/j.trre.2014.03.002
69. Letavernier E, Bruneval P, Vandermeersch S, Perez J, Mandet C, Belair MF et al (2009) Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Renal Assoc 24(2):630–8. doi:10.1093/ndt/gfn574
70. Oroszlan M, Bieri M, Ligeti N, Farkas A, Meier B, Marti HP et al (2010) Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway. Transpl Immunol 23(3):125–32. doi:10.1016/j.trim.2010.05.003
71. Cina DP, Onay T, Paltoo A, Li C, Maezawa Y, De Arteaga J et al (2012) Inhibition of MTOR disrupts autophagic flux in podocytes. J Am Soc Nephrol JASN 23(3):412–20. doi:10.1681/ASN.2011070690
72. Kirsch AH, Riegelbauer V, Tagwerker A, Rudnicki M, Rosenkranz AR, Eller K (2012) The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response. Am J Physiol Renal Physiol 303(4):F569–75. doi:10.1152/ajprenal.00180.2012
73. Arnau A, Ruiz JC, Rodrigo E, Quintanar JA, Arias M (2011) Is proteinuria reversible, after withdrawal of mammalian target of rapamycin inhibitors? Transplant Proc 43(6):2194–5. doi:10.1016/j.transproceed.2011.06.045
74. Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, Mitchell SS et al (2010) FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 15(4):428–35. doi:10.1634/theoncologist.2009-0178
75. Gerullis H, Bergmann L, Maute L, Eimer C, Otto T (2009) Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany. Cancer Chemother Pharmacol 63(6):1097–102. doi:10.1007/s00280-008-0835-2
76. Li G, Shan C, Liu L, Zhou T, Zhou J, Hu X et al (2015) Tanshinone IIA inhibits HIF-1alpha and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway. PLoS One 10(2), e0117440. doi:10.1371/journal.pone.0117440
77. Weidemann A, Bernhardt WM, Klanke B, Daniel C, Buchholz B, Campean V et al (2008) HIF activation protects from acute kidney injury. J Am Soc Nephrol JASN 19(3):486–94. doi:10.1681/ASN.2007040419
78. Uthurriague C, Thellier S, Ribes D, Rostaing L, Paul C, Meyer N (2014) Vemurafenib significantly decreases glomerular filtration rate. J Eur Acad Dermatol Venereol JEADV 28(7):978–9. doi:10.1111/jdv.12322
79. Launay-Vacher V, Zimner-Rapuch S, Poulalhon N, Fraisse T, Garrigue V, Gosselin M et al (2014) Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients. Cancer 120(14):2158–63. doi:10.1002/cncr.28709
80. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–703. doi:10.1056/NEJMoa1006448
81. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ et al (2014) Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370(13):1189–97. doi:10.1056/NEJMoa1311107
82. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30(8):863–70. doi:10.1200/JCO.2011.35.6345
83. Lin YT, Wang YF, Yang JC, Yu CJ, Wu SG, Shih JY et al (2014) Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J Thorac Oncol 9(11):1720–5. doi:10.1097/JTO.0000000000000326
84. Schnell P, Bartlett CH, Solomon BJ, Tassell V, Shaw AT, de Pas T et al (2015) Complex renal cysts associated with crizotinib treatment. Cancer Med. doi:10.1002/cam4.437
85. Horie S, Higashihara E, Nutahara K, Mikami Y, Okubo A, Kano M et al (1994) Mediation of renal cyst formation by hepatocyte growth factor. Lancet 344(8925):789–91
86. Klempner SJ, Aubin G, Dash A, Ou SH (2014) Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment. Oncologist 19(9):1008–10. doi:10.1634/theoncologist.2014-0216
87. Shaw AT, Engelman JA (2014) Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370(26):2537–9. doi:10.1056/NEJMc1404894
88. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507–16. doi:10.1056/NEJMoa1306220
89. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–23. doi:10.1056/NEJMoa1003466
90. Izzedine H, Gueutin V, Gharbi C, Mateus C, Robert C, Routier E et al (2014) Kidney injuries related to ipilimumab. Investig New Drugs 32(4):769–73. doi:10.1007/s10637-014-0092-7
91. Fadel F, El Karoui K, Knebelmann B (2009) Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 361(2):211–2. doi:10.1056/NEJMc0904283
92. Lute KD, May KF Jr, Lu P, Zhang H, Kocak E, Mosinger B et al (2005) Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood 106(9):3127–33. doi:10.1182/blood-2005-06-2298
93. Bhaumik SK, Kher V, Arora P, Rai PK, Singhal M, Gupta A et al (1996) Evaluation of clinical and histological prognostic markers in drug-induced acute interstitial nephritis. Ren Fail 18(1):97–104